We found that bosutinib inhibited NB cell proliferation and blocked the activation of Src and c-Abl, as well as the PI3K/AKT/mTOR, MAPK/ERK, and JAK/STAT3 signaling pathways in all NB cell lines tested. Here, ABL1 is linked to neuroblastoma.